<DOC>
	<DOC>NCT01895426</DOC>
	<brief_summary>The purpose of this study is to collect clinical and radiological mid-term (2 years) data on the ArcadiusXP L® lumbar stand-alone cage in a post-market clinical follow-up study (PMCF) limited to 32 patients.</brief_summary>
	<brief_title>ArcadiusXP L Post Market Clinical Follow-Up</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>all indications as given by the instructions for use Patients with persisting lumbosacral and pseudoradicular pain scheduled for monosegmental lumbar interbody fusion from L4 to S1 Age 18 60 at least 6 months of unsuccessful treatment including conservative measures Nonsequestrated and subligamentous prolapse all contraindications, which are listed in the instructions for use. existing pregnancy, planned or occurring during study period patients with a higher degree of segmental degeneration in other than the segment to be operated body massindex (BMI) &gt; 30 Systemic or local infection Increased risk of osteoporosis according to assessment by the SCORE evaluation Bone metabolism disorders Chemotherapy or radiotherapy (ongoing or planned) Participation in another clinical trial Scheduled for spinal litigation Other serious conditions that hinder the participation in the study Nanogel® filling of the cage, prior to implantation was not done</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>